Immune-Based Lymphoma Treatment Sho... (nths to develop. Each patient received f...)

Immune-Based Lymphoma Treatment Shows Promise

Date:5/31/2009

nths to develop. Each patient received five injections over six months.

"The vaccine targets the 'idiotype' protein on the cell surface [of cancerous B cells in follicular lymphoma]. The protein is unique to cancer cells and varies from patient to patient," Schuster explained. "The idiotype vaccine with the immune stimulatory molecules improved disease-free survival following chemo."

However, in contrast to other phase III trials involving cancer vaccines, "remission before receiving the vaccine might be a prerequisite for deriving benefit, or at least statistically significant benefit," he added.

Another phase III trial for another cancer vaccine -- this one for advanced melanoma -- also produced promising results, marking the first evidence of clinical benefit of vaccination in patients with melanoma.

This time, researchers added a new cancer vaccine, called gp100:209-217(210M) peptide, to conventional therapy.

"In the past, what we've tried to do in the cancer immunology field is to attack tumors one agent at a time. Now we're starting to combine agents together for effective therapy," said study senior author Dr. Patrick Hwu, melanoma chief at the University of Texas M.D. Anderson Cancer Center in Houston. "Our approach here was to combine the vaccine with interleukin 2 to get immune cells to attack the tumor. All immune approaches try to get killer T-cells to attack the tumor. The vaccine allows the 'soldiers' to go through boot camp, [it] initiates the training of soldiers. The soldiers then multiply into a large army that can then attack tumors to kill them."

Patients receiving the vaccine had longer overall survival -- 17.6 months vs. 12.8 months for controls -- but that was not considered statistically significant. They also experienced a progression-free survival of 2.9 months vs. 1.6 months for those who didn't get the vaccine. Better still, 22 percent saw their tumors shrink, as compared with
'/>"/>

1

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Immune-based drug approved in Europe for pediatric cancer patients
2. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
3. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
4. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
5. January 1 Looms Large for Lymphoma Patients
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. Possible Cure for Rare Lymphoma Reported
8. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
9. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
10. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
11. Lymphoma drug used to treat skin disorders

Post Your Comments:

Immune-Based Lymphoma Treatment Sho...(nths to develop. Each patient received f...),Health